|
Pfizer Gets Complete Response Letter for Neuro Drug Vyndaqel
Pfizer has received a complete response letter from the FDA on its neuro drug Vyndaqel (tafamidis) after a negative advisory panel meeting, with agency staff and advisers raising concerns about the drug’s efficacy.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives